Genetically Engineered Dendritic Cells Sustaining Immune Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell (DC) therapies are limited by their short immune stimulatory window, as DCs transition from an immune stimulatory to an immune suppressive phenotype after 24 hours, making them inadequate for therapeutic interventions requiring sustained immune activation, such as cancer immunotherapy or microbial disease treatment.
Innovation Solution
Genetic engineering of dendritic cells to over-express immune stimulatory molecules and knock down immune suppressive molecules, extending the immune stimulatory window by maintaining IL-12 secretion and preventing the expression of molecules that mediate immune suppression, allowing for prolonged T-cell stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If dendritic cells are used for immune therapy, then immune stimulation is achieved, but the immune stimulatory effect is lost after 24 hours due to phenotypic transition to immune suppression
Solution Approach 1:
The patent applies preliminary action by genetically engineering dendritic cells before their natural phenotypic transition can occur. Specifically, the invention introduces nucleic acid molecules encoding immune stimulatory molecules (such as IL-12, IL-18, TNF-alpha, or CD40L) into immature or semi-mature dendritic cells, thereby pre-programming them to maintain immune stimulatory function even after 24 hours when they would normally transition to an immune suppressive phenotype. This preliminary genetic modification ensures sustained therapeutic effect without requiring continuous external stimulation.
2Duration of action of moving object
If dendritic cells are genetically engineered to over-express immune stimulatory molecules, then T-cell activation is prolonged, but the complexity of cell production increases
Solution Approach 1:
The patent applies parameter changes by modifying the molecular composition parameters of dendritic cells through genetic engineering. The invention changes the expression levels of specific cytokines and co-stimulatory molecules (IL-12, IL-18, TNF-alpha, CD40L) within the dendritic cells, thereby altering their functional parameters. This allows prolonged T-cell activation without fundamentally changing the dendritic cell production process architecture, maintaining relative simplicity while achieving extended therapeutic effect.
Data Source
AI summary
The present invention relates to a method for producing dendritic cells and their use in medicaments by genetic engineering aimed at functionally improving their therapeutic efficacy in the treatment of cancer, microbial infections, allergies, auto-immune diseases or organ and stem cell transplant rejection.